Why Ardent Health stock is back in focus after fresh 2026 guidance

Ardent Health (ARDT) is back on investor watchlists after reporting record 2025 revenue, EBITDA, and operating cash flow, alongside new 2026 guidance that points to steady earnings despite industry cost and reimbursement pressures.

Despite the fresh 2026 guidance and the new AI assisted virtual care partnership with hellocare.ai, Ardent Health’s short term share price return has been weak. The stock recorded a 1 day move of 5.72% lower and a 7 day share price return of 5.22% lower, while the 90 day share price return of 3.73% higher contrasts with a 1 year total shareholder return of 38.96% lower, suggesting recent momentum is still trying to rebuild after a tougher year.

If Ardent’s update has you rethinking your exposure to healthcare and AI, it could be a good moment to scan 32 healthcare AI stocks for potential alternatives or complements.

With Ardent Health guiding to 2026 revenue of US$6,400 million to US$6,700 million and trading below some published price targets, is this an underappreciated hospital operator, or a stock where the market already sees the growth story?

Most Popular Narrative: 31.9% Undervalued

At a last close of $8.90 against a narrative fair value of $13.07, the current price sits well below what this widely followed model suggests.

Company investments in expanding the ambulatory and urgent care footprint, with ongoing projects and recent acquisitions, enable access to higher margin outpatient services and enlarge Ardent's patient base, driving a sustained increase in net margins and diversified recurring revenues.

Curious how a hospital operator ends up with this kind of gap to fair value? The narrative leans heavily on steadier margins, larger scale, and a different earnings mix than today. The full set of revenue, earnings and valuation assumptions sit under that headline number.

Result: Fair Value of $13.07 (UNDERVALUED)

However, this hinges on payer disputes and regulatory outcomes. Tougher reimbursement terms or changes to Medicaid support could quickly chip away at the margin story investors are watching.

Another View: Cash Flows Tell A Different Story

While the narrative fair value sits at $13.07, Simply Wall St’s DCF model points the other way. On that cash flow view, Ardent Health at $8.90 is trading above an estimated value of $6.28, which frames the stock as overvalued rather than undervalued. So which lens do you trust more: earnings power or cash generation?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Ardent Health for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of upside and risk feels finely balanced to you, do not wait around to see how others react. Instead, check the 4 key rewards and 1 important warning sign and weigh the trade off for yourself.

Looking for more investment ideas?

You do not need to sit on your hands after reading one stock update. Use the tools available and line up your next set of research targets.

• Target resilience by checking companies on our 63 resilient stocks with low risk scores and see which names rank well on stability and risk controls.
• Hunt for quality at a discount using the screener containing 24 high quality undiscovered gems to spot lesser known businesses with fundamentals that may warrant a closer look.
• Focus on financial strength by scanning the solid balance sheet and fundamentals stocks screener (41 results) for companies that pair manageable debt with healthier looking balance sheets.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.